Saturday , May 8 2021

The synergistic effect of a combination of inhibitors of DPP4 diabetes + TZD & apos;



[의학신문·일간보사=김상일 기자]Takeda Pharmaceutical Korea announced on October 27th and 28th that she presented the latest research on the "Strategy for Type 2 Diabetes Management and Effective Therapy" in Paradise Citi Incheon and shared the opinions of experts.

In particular, the symposium considered an ideal combination therapy based on clinical evidence. Lately, with the introduction of various regimens of treatment, such as TKD, incretin therapy (GLP-1 receptor agonist and DPP-4 inhibitor) and SGLT-2 inhibitor, the choice of drugs given the individual characteristics of patients with diabetes has spread, the discussion is based on literature.

"TZD is a combination of TZD and SGLT2 inhibitors," said Professor Jeong-hiun, from Inje University, Pusan ​​Paik University. "TZD can reduce the risk of myocardial infarction or stroke, which is the lack of inhibitor SGLT2, the SGLT2 inhibitor compensates for the deficiencies in weight gain of TZD and edema."

"DPP4 inhibitor and TZD are a good combination to improve at least 6 pathophysiological disorders, such as increased insulin sensitivity and incretin effect among several combinations, and there is little risk of hypoglycaemia. It is a combination that is strong, continuous and has a safety profile of cardiovascular disease."

In fact, several studies have shown that TZD improves the function of beta cells by preventing the death of beta cells by reducing not only the toxicity of blood glucose but also the lipid toxicity, a powerful insulin sensitizer that improves blood glucose control in patients with type 2 diabetes.

At this symposium lectures and discussions about the importance of maintaining the therapeutic effect in diabetes management, the truth and misunderstanding of TZD (thiazolidinedione) and the ideal combination therapy were discussed.

Professor Lim, who is in charge of the persistence of diabetes, explained that "the importance of preserving beta cells in the early treatment of diabetes mellitus is an important long-term effect for patients. Pioglitazone is a beta cell" It is a medicine that has shown to have a good effect on maintaining diabetes " , he said.

After that, Professor Lee Eun-jung of Kangbuk University of Samsung Sungkiunkvan University Hospital said: "Fat accumulation in the liver, pancreas, and myocardium reduces the function of the body." Pioglitazone has already been shown in many studies to reduce visceral fat and replaced it with subcutaneous fat. "

Kim Sang Il reporter [email protected]

<저작권자 © 의학신문, 무단 전재 및 재배포 금지>


Source link